title: Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.
abstract: BACKGROUND
  Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during assisted reproductive technology protocols. The aim of this study was to evaluate the role of dopamine agonist as a preventive strategy of OHSS in women at high risk in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment cycles.
  
  
  METHODS
  Seventy women at risk to develop OHSS undergoing IVF/ICSI treatment cycle were included. The study group received 0.5 mg of cabergoline for 8 days from the day of human chorionic gonadotropin administration in comparison to those who undergo no treatment for the prevention of OHSS. The reduction of the incidence of OHSS was the primary outcome.
  
  
  RESULTS
  The actual incidence of OHSS was 8.33% in the cabergoline group and 20.58% in the control group. Thus, the incidence of OHSS was significantly reduced, by almost 60%, in the cabergoline group in comparison with the control group (relative ratios: 0.4, 95% confidence interval: 0.18-0.79).
  
  
  CONCLUSIONS
  Prophylactic treatment with the dopamine agonist, cabergoline, reduces the incidence of OHSS in women at high risk undergoing IVF/ICSI treatment. However, the effects of cabergoline on important outcomes, namely, live birth, miscarriage, and congenital abnormalities are still uncertain.
authors.affiliation: Department of Obstetrics and Gynecology, Suleymaniye Maternity and Children's Teaching and Research Hospital, Istanbul, Turkey.
authors.forename: Niyazi
authors.initials: N
authors.lastname: Kılıç
authors.affiliation: Department of Obstetrics and Gynecology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
authors.forename: Özhan
authors.initials: Ö
authors.lastname: Özdemir
authors.affiliation: Department of Obstetrics and Gynecology, Suleymaniye Maternity and Children's Teaching and Research Hospital, Istanbul, Turkey.
authors.forename: Hakan Cevdet
authors.initials: HC
authors.lastname: Başar
authors.affiliation: Department of Obstetrics and Gynecology, Suleymaniye Maternity and Children's Teaching and Research Hospital, Istanbul, Turkey.
authors.forename: Fadime
authors.initials: F
authors.lastname: Demircan
authors.affiliation: Department of Obstetrics and Gynecology, Suleymaniye Maternity and Children's Teaching and Research Hospital, Istanbul, Turkey.
authors.forename: Fırat
authors.initials: F
authors.lastname: Ekmez
authors.affiliation: Department of Obstetrics and Gynecology, Suleymaniye Maternity and Children's Teaching and Research Hospital, Istanbul, Turkey.
authors.forename: Oğuz
authors.initials: O
authors.lastname: Yücel
keywords: Cabergoline; ovarian hyperstimulation; vascular endothelial growth factor